Benitec Biopharma Says FDA Requested More Data On Single-Arm Pivotal Study Of BB-301 In Oculopharyngeal Muscular Dystrophy; Expects Final Design In Q1 2027

Loading news article.

Benitec Biopharma Says FDA Requested More Data On Single-Arm Pivotal Study Of BB-301 In Oculopharyngeal Muscular Dystrophy; Expects Final Design In Q1 2027 | WAPE

Benitec Biopharma Says FDA Requested More Data On Single-Arm Pivotal Study Of BB-301 In Oculopharyngeal Muscular Dystrophy; Expects Final Design In Q1 2027

Article summary

Related companies

Comments —